Shih, Angela R.
Nitiwarangkul, Chayanin
Little, Brent P.
Roop, Benjamin W.
Nandy, Sreyankar
Szabari, Margit V.
Mercaldo, Nathaniel
Mercaldo, Sarah
Montesi, Sydney B.
Muniappan, Ashok
Berigei, Sarita R.
Lynch, David A.
Sharma, Amita
Hariri, Lida P.
Funding for this research was provided by:
National Institutes of Health (K23HL132120)
National Institutes of Health (R01HL152075)
Article History
Received: 25 September 2020
Accepted: 22 February 2021
First Online: 26 April 2021
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board, and need for individual patient consent was waived.
: No individual person’s data is present in this manuscript.
: Drs. Shih, Nitiwarangkul, Little, Nandy, Szabari, Mercaldo, Mercaldo, Montesi, Muniappan, and Mr. Roop and Ms. Berigei declare no conflicts of interest. Dr Lynch has served as a consultant for Boehringer Ingelheim Inc, Veracyte Inc, and Parexel Inc. Dr. Montesi has received funding through her institution form Merck, United Therapeutics, and Promedior, and has received royalties from Wolters Kluwer. Dr. Sharma has grant support from Hummingbird Diagnostics (unrelated to this work). Dr. Hariri has served as a consultant for Biogen Idec, and serves as a consultant for Boehringer Ingelheim and Pliant Therapeutics; Dr. Hariri also receives grant funding from Boehringer Ingelheim.